SAB Biotherapeutics (SABS) Cash & Equivalents (2020 - 2026)

SAB Biotherapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $20.5 million for Q1 2026.

• Quarterly Cash & Equivalents rose 263.8% year-over-year to $20.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.5 million (up 263.8% YoY) and the FY2025 annual result came in at $10.5 million, up 18.03% from the prior year.
• Cash & Equivalents was $20.5 million for Q1 2026 at SAB Biotherapeutics, up from $10.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $56.6 million in Q4 2023 and bottomed at $2.4 million in Q3 2023.
• A 5-year average of $15.4 million and a median of $13.1 million in 2023 frame the typical range for Cash & Equivalents.
• Peak annual rise in Cash & Equivalents reached 278.12% in 2024, while the deepest fall reached 84.27% in 2024.
• SAB Biotherapeutics' Cash & Equivalents stood at $15.0 million in 2022, then jumped by 275.93% to $56.6 million in 2023, then tumbled by 84.27% to $8.9 million in 2024, then climbed by 18.03% to $10.5 million in 2025, then soared by 95.38% to $20.5 million in 2026.
• Business Quant data shows SABS's Cash & Equivalents at $20.5 million in Q1 2026, $10.5 million in Q4 2025, and $29.4 million in Q3 2025.